野村发表研究报告指,以现金流折现率计,将康方生物(09926.HK) 目标价由75.14元升至99.66元,惟评级由“买入”降至“中性”。该行解释,上调目标价是因为公司的抗肺癌药物依沃西单抗(ivonescimab)用于PD-L1阳性的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(sNDA),已获得中国...
Source Link野村发表研究报告指,以现金流折现率计,将康方生物(09926.HK) 目标价由75.14元升至99.66元,惟评级由“买入”降至“中性”。该行解释,上调目标价是因为公司的抗肺癌药物依沃西单抗(ivonescimab)用于PD-L1阳性的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(sNDA),已获得中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.